Logo image of BGM

BGM GROUP LTD (BGM) Stock Fundamental Analysis

NASDAQ:BGM - Nasdaq - KYG7307E1237 - Common Stock - Currency: USD

10.73  +0.14 (+1.37%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to BGM. BGM was compared to 192 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for BGM as it has an excellent financial health rating, but there are worries on the profitability. BGM has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

BGM had negative earnings in the past year.
BGM had a positive operating cash flow in the past year.
In multiple years BGM reported negative net income over the last 5 years.
BGM had a positive operating cash flow in each of the past 5 years.
BGM Yearly Net Income VS EBIT VS OCF VS FCFBGM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M

1.2 Ratios

BGM has a better Return On Assets (-2.72%) than 78.65% of its industry peers.
With an excellent Return On Equity value of -3.38%, BGM belongs to the best of the industry, outperforming 81.25% of the companies in the same industry.
Industry RankSector Rank
ROA -2.72%
ROE -3.38%
ROIC N/A
ROA(3y)-5.41%
ROA(5y)-0.31%
ROE(3y)-6.51%
ROE(5y)1.12%
ROIC(3y)N/A
ROIC(5y)N/A
BGM Yearly ROA, ROE, ROICBGM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 30

1.3 Margins

With a Gross Margin value of 16.39%, BGM perfoms like the industry average, outperforming 51.56% of the companies in the same industry.
BGM's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for BGM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 16.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y18.4%
GM growth 5Y-4.83%
BGM Yearly Profit, Operating, Gross MarginsBGM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20

More info and screens

8

2. Health

2.1 Basic Checks

BGM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BGM has more shares outstanding
The number of shares outstanding for BGM has been reduced compared to 5 years ago.
BGM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BGM Yearly Shares OutstandingBGM Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
BGM Yearly Total Debt VS Total AssetsBGM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

An Altman-Z score of 62.12 indicates that BGM is not in any danger for bankruptcy at the moment.
BGM has a better Altman-Z score (62.12) than 97.92% of its industry peers.
BGM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 62.12
ROIC/WACCN/A
WACC8.27%
BGM Yearly LT Debt VS Equity VS FCFBGM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M 40M 50M

2.3 Liquidity

A Current Ratio of 3.39 indicates that BGM has no problem at all paying its short term obligations.
BGM has a Current ratio (3.39) which is comparable to the rest of the industry.
A Quick Ratio of 2.82 indicates that BGM has no problem at all paying its short term obligations.
BGM's Quick ratio of 2.82 is in line compared to the rest of the industry. BGM outperforms 53.65% of its industry peers.
Industry RankSector Rank
Current Ratio 3.39
Quick Ratio 2.82
BGM Yearly Current Assets VS Current LiabilitesBGM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 82.89% over the past year.
Looking at the last year, BGM shows a very negative growth in Revenue. The Revenue has decreased by -45.99% in the last year.
The Revenue for BGM have been decreasing by -11.45% on average. This is quite bad
EPS 1Y (TTM)82.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.03%
Revenue 1Y (TTM)-45.99%
Revenue growth 3Y-23.97%
Revenue growth 5Y-11.45%
Sales Q2Q%-27.57%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BGM Yearly Revenue VS EstimatesBGM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
BGM Yearly EPS VS EstimatesBGM Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BGM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BGM Price Earnings VS Forward Price EarningsBGM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BGM indicates a somewhat cheap valuation: BGM is cheaper than 75.00% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 1509.81
BGM Per share dataBGM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BGM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BGM GROUP LTD

NASDAQ:BGM (3/7/2025, 8:07:24 PM)

10.73

+0.14 (+1.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.01%
Inst Owner ChangeN/A
Ins Owners3.58%
Ins Owner ChangeN/A
Market Cap1.04B
AnalystsN/A
Price TargetN/A
Short Float %0.59%
Short Ratio0.75
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.08
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 41.56
P/FCF N/A
P/OCF 1916.89
P/B 24.41
P/tB 27.3
EV/EBITDA 1509.81
EPS(TTM)-0.2
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0.01
OCFY0.05%
SpS0.26
BVpS0.44
TBVpS0.39
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.72%
ROE -3.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 16.39%
FCFM N/A
ROA(3y)-5.41%
ROA(5y)-0.31%
ROE(3y)-6.51%
ROE(5y)1.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y18.4%
GM growth 5Y-4.83%
F-Score5
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 106.56%
Cap/Sales 5.25%
Interest Coverage N/A
Cash Conversion 80.81%
Profit Quality N/A
Current Ratio 3.39
Quick Ratio 2.82
Altman-Z 62.12
F-Score5
WACC8.27%
ROIC/WACCN/A
Cap/Depr(3y)184.23%
Cap/Depr(5y)176.99%
Cap/Sales(3y)4.89%
Cap/Sales(5y)4.34%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)82.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.03%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-45.99%
Revenue growth 3Y-23.97%
Revenue growth 5Y-11.45%
Sales Q2Q%-27.57%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y78.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y55.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y74.31%
OCF growth 3Y15.85%
OCF growth 5YN/A